CHOSA Oncology targets US market with Platin-DRP diagnostic test
CHOSA Oncology has signed an agreement with a CLIA-certified laboratory to validate its Platin-DRP biomarker test in the US, with initial revenues projected for summer 2027.
CHOSA Oncology AB has entered into a partnership with a CLIA-certified laboratory to develop and validate its Platin-DRP product as a laboratory-developed test (LDT) for the US market. This collaboration serves as a entry point for the company to offer its platinum-response biomarker to clinical practitioners in the United States.
Platinum-based chemotherapy remains a standard treatment for lung cancer, despite significant variability in patient outcomes. By providing a diagnostic tool that identifies likelihood of drug response, the company aims to address a long-standing gap in oncology treatment selection.
The timeline for commercialization remains subject to successful analytical validation of the test. CHOSA projects that the first revenue streams from the US operations will commence in the summer of 2027.